Finch Therapeutics Group Stock (NASDAQ:FNCH)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$12.13

52W Range

$0.80 - $14.26

50D Avg

$11.90

200D Avg

$5.04

Market Cap

$19.35M

Avg Vol (3M)

$10.37K

Beta

1.33

Div Yield

-

FNCH Company Profile


Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

1

IPO Date

Mar 19, 2021

Website

FNCH Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 22Dec 21
Collaboration Revenue$861.00K$18.53M
Royalties Revenue From Related Party--

Fiscal year ends in Dec 23 | Currency in USD

FNCH Financial Summary


Dec 23Dec 22Dec 21
Revenue$107.00K$861.00K$18.53M
Operating Income$-83.86M$-115.59M$-59.98M
Net Income$-74.75M$-113.70M$-55.86M
EBITDA$-83.86M$-74.65M$-59.98M
Basic EPS$-0.05$-71.52$-42.75
Diluted EPS$-0.05$-71.52$-42.75

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
NTRBNutriband Inc.
DBTXDecibel Therapeutics, Inc.
BWVOnconetix, Inc.
IKNAIkena Oncology, Inc.
EWTXEdgewise Therapeutics, Inc.
STOKStoke Therapeutics, Inc.
KPRXKiora Pharmaceuticals, Inc.
LGVNLongeveron Inc.
REVBRevelation Biosciences, Inc.
QNRXQuoin Pharmaceuticals, Ltd.
HILSTharimmune, Inc.
CCCCC4 Therapeutics, Inc.
VRAXVirax Biolabs Group Limited
GLUEMonte Rosa Therapeutics, Inc.
DSGNDesign Therapeutics, Inc.
RNXTRenovoRx, Inc.
HOWLWerewolf Therapeutics, Inc.
XLOXilio Therapeutics, Inc.
CELCCelcuity Inc.
ELYMEliem Therapeutics, Inc.